

# Drug Addiction Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/D4C681E57126EN.html>

Date: March 2022

Pages: 194

Price: US\$ 2,000.00 (Single User License)

ID: D4C681E57126EN

## Abstracts

Drug Addiction Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

### SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Drug Addiction - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Drug Addiction (Central Nervous System) pipeline landscape.

Drug addiction, also called substance dependence or chemical dependency, is a disease that is characterized by a destructive pattern of drug abuse that leads to significant problems involving tolerance to or withdrawal from the substance. Drug addiction symptoms or behaviors include recurrent drug use that results in a lack of meeting important obligations at work, school, or home, inability to sleep, awake at unusual times, unusual laziness, loss of or increased in appetite, changes in eating habits, cold, sweaty palms; shaking hands., red, watery eyes; pupils larger or smaller than usual and unusual smells on breath, body or clothes.

### REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Drug Addiction - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Drug Addiction (Central Nervous System), complete with

analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Drug Addiction (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Drug Addiction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 11, 15, 3, 35 and 10 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 11 and 3 molecules, respectively.

Drug Addiction (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

**Note:** Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Drug Addiction (Central Nervous System).

The pipeline guide reviews pipeline therapeutics for Drug Addiction (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Drug Addiction (Central Nervous System) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Drug Addiction (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Drug Addiction (Central Nervous System)

## **REASONS TO BUY**

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Drug Addiction (Central Nervous System).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Drug Addiction (Central Nervous System) pipeline depth and focus of Indication

therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

## Contents

- Introduction
- Global Markets Direct Report Coverage
- Drug Addiction - Overview
- Drug Addiction - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Drug Addiction - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Drug Addiction - Companies Involved in Therapeutics Development
- Adjuvance Technologies Inc
- Aelis Farma SAS
- Aether Therapeutics Inc
- Allaysis LLC
- Amygdala Neurosciences Inc
- Ananda Scientific Inc
- Aphios Corp
- Assertio Holdings Inc
- Astraea Therapeutics LLC
- Better Life Pharmaceuticals Inc
- BioCorRx Inc
- Camino Pharma LLC
- Cerevel Therapeutics Holdings Inc
- Charleston Laboratories Inc
- Chiesi Farmaceutici SpA
- Chiromics LLC
- Clear Scientific LLC
- Consegna Pharma Inc
- Curemark LLC
- D&A Pharma SAS
- Daya Drug Discoveries Inc
- DD Therapeutics LLC

Delix Therapeutics Inc  
Denovo Biopharma LLC  
Elysium Therapeutics Inc  
Embera NeuroTherapeutics Inc  
EncepHeal Therapeutics Inc  
Ensysce Biosciences Inc  
Entheon Biomedical Corp  
EryDel SpA  
F. Hoffmann-La Roche Ltd  
Foresee Pharmaceuticals Co Ltd  
Hua Medicine Shanghai Ltd  
IMV Inc  
InterveXion Therapeutics LLC  
Intra-Cellular Therapies Inc  
Jazz Pharmaceuticals Plc  
Kdac Therapeutics Inc  
KemPharm Inc  
Kinaxis Therapeutics Pty Ltd  
Kyorin Pharmaceutical Co Ltd  
MAKScientific LLC  
MEIkin Pharmaceuticals  
Mind Medicine MindMed Inc  
Mydecine Innovations Group Inc  
Myosin Therapeutics Inc  
Naprogenix Inc  
NFL Biosciences SAS  
Novartis AG  
Omeros Corp  
Ovid Therapeutics Inc  
P2D Inc  
PAION AG  
Proniras Corp  
Protagenic Therapeutics Inc  
Qingdao Primedicine Pharmaceutical Technology Co Ltd  
Relmada Therapeutics Inc  
Revive Therapeutics Ltd  
Saniona AB  
Sen-Jam Pharmaceutical LLC  
Tonix Pharmaceuticals Holding Corp

Trevena Inc

Tris Pharma Inc

Vallon Pharmaceuticals Inc

Vivozon Inc

Zelira Therapeutics Ltd

Drug Addiction - Drug Profiles

(hydrocodone bitartrate + naltrexone hydrochloride) - Drug Profile

Product Description

Mechanism Of Action

History of Events

(metyrapone + oxazepam) - Drug Profile

Product Description

Mechanism Of Action

History of Events

6-BN - Drug Profile

Product Description

Mechanism Of Action

History of Events

AEF-0117 - Drug Profile

Product Description

Mechanism Of Action

History of Events

AM-4113 - Drug Profile

Product Description

Mechanism Of Action

History of Events

AM-4302 - Drug Profile

Product Description

Mechanism Of Action

History of Events

ANS-6637 - Drug Profile

Product Description

Mechanism Of Action

History of Events

AT-1001 - Drug Profile

Product Description

Mechanism Of Action

History of Events

AT-121 - Drug Profile

Product Description  
Mechanism Of Action  
History of Events  
AT-200 - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
AT-312 - Drug Profile  
Product Description  
Mechanism Of Action  
baclofen - Drug Profile  
Product Description  
Mechanism Of Action  
BETR-002 - Drug Profile  
Product Description  
Mechanism Of Action  
BICX-102 - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
Biologic to Agonize TLR4 for Drug Addiction - Drug Profile  
Product Description  
Mechanism Of Action  
buprenorphine - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
cannabidiol - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
cannabidiol - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
cannabidiol - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events



CC-318 - Drug Profile

Product Description

Mechanism Of Action

cebranopadol - Drug Profile

Product Description

Mechanism Of Action

History of Events

CHF-6563 - Drug Profile

Product Description

Mechanism Of Action

History of Events

CM-1212 - Drug Profile

Product Description

Mechanism Of Action

CS-1103 - Drug Profile

Product Description

Mechanism Of Action

History of Events

CVL-354 - Drug Profile

Product Description

Mechanism Of Action

History of Events

CVL-936 - Drug Profile

Product Description

Mechanism Of Action

History of Events

CYD-179 - Drug Profile

Product Description

Mechanism Of Action

DDD-024 - Drug Profile

Product Description

Mechanism Of Action

dimethyltryptamine - Drug Profile

Product Description

Mechanism Of Action

DLX-7 - Drug Profile

Product Description

Mechanism Of Action

dronabinol - Drug Profile

Product Description

Mechanism Of Action

History of Events

Ery-CoCe - Drug Profile

Product Description

Mechanism Of Action

esmethadone hydrochloride - Drug Profile

Product Description

Mechanism Of Action

History of Events

FP-004 - Drug Profile

Product Description

Mechanism Of Action

Gene Therapy for Methamphetamine Abuse - Drug Profile

Product Description

Mechanism Of Action

Gene Therapy to Activate Cocaine Hydrolase for Cocaine Abuse and Addiction - Drug Profile

Product Description

Mechanism Of Action

History of Events

h-2E2 - Drug Profile

Product Description

Mechanism Of Action

History of Events

ibudilast - Drug Profile

Product Description

Mechanism Of Action

History of Events

ITI-333 - Drug Profile

Product Description

Mechanism Of Action

History of Events

IXTM-200 - Drug Profile

Product Description

Mechanism Of Action

History of Events

IXTm-250 - Drug Profile

Product Description

Mechanism Of Action  
IXTV-100 - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
JDTic - Drug Profile  
Product Description  
Mechanism Of Action  
JJC-8091 - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
KDAC-0001 - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
KNX-100 - Drug Profile  
Product Description  
Mechanism Of Action  
KNX-300 - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
KNX-400 - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
KP-879 - Drug Profile  
Product Description  
Mechanism Of Action  
mavoglurant - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
MC-100093 - Drug Profile  
Product Description  
Mechanism Of Action  
MP-1104 - Drug Profile  
Product Description

Mechanism Of Action  
MT-110 - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
MYCO-004 - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
naloxone - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
NFL-201 - Drug Profile  
Product Description  
Mechanism Of Action  
NS-2359 - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
OMS-527 - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
OV-329 - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
oxycodone hydrochloride - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
oxytocin - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
PMS-001 - Drug Profile  
Product Description  
Mechanism Of Action

pomaglumetad methionil - Drug Profile

Product Description

Mechanism Of Action

History of Events

psilocybin - Drug Profile

Product Description

Mechanism Of Action

PT-00114 - Drug Profile

Product Description

Mechanism Of Action

History of Events

Recombinant Enzyme for Cocaine Abuse - Drug Profile

Product Description

Mechanism Of Action

remimazolam besylate - Drug Profile

Product Description

Mechanism Of Action

History of Events

RO-5256390 - Drug Profile

Product Description

Mechanism Of Action

History of Events

SBP-0069330 - Drug Profile

Product Description

Mechanism Of Action

History of Events

SJP-005 - Drug Profile

Product Description

Mechanism Of Action

Small Molecule to Agonize MOR1 for Pain and Substance (Drug) Abuse - Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecule to Antagonize Mu Opioid Receptor for Drug Abuse, Alcohol Addiction and OIC - Drug Profile

Product Description

Mechanism Of Action

Small Molecules for Drug Abuse - Drug Profile

Product Description

Mechanism Of Action

Small Molecules for Substance Abuse and Drug Overdose - Drug Profile

Product Description

Mechanism Of Action

Small Molecules to Agonize CB1 and CB2 for CNS Diseases and Oncology - Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecules to Antagonize mGLUR5 for Central Nervous System Disorders - Drug Profile

Product Description

Mechanism Of Action

Small Molecules to Inhibit CB1 Receptor for Cannabinoid Abuse and Drug Addiction - Drug Profile

Product Description

Mechanism Of Action

Small Molecules to Inhibit DAT for Substance Abuse - Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecules to Scavenge Free Radicals for Oxidative Stress Related Disorders - Drug Profile

Product Description

Mechanism Of Action

sodium oxybate IR - Drug Profile

Product Description

Mechanism Of Action

Synthetic Peptide to Inhibit ELK1 for Central Nervous System Disorders - Drug Profile

Product Description

Mechanism Of Action

Synthetic Peptide to Target Kappa Opioid Receptors for Drug Addiction - Drug Profile

Product Description

Mechanism Of Action

tezampanel - Drug Profile

Product Description

Mechanism Of Action

History of Events

Titerquil-1055 - Drug Profile

Product Description

Mechanism Of Action

History of Events

TNX-1300 - Drug Profile

Product Description

Mechanism Of Action

History of Events

TRV-734 - Drug Profile

Product Description

Mechanism Of Action

History of Events

Vaccine for Cocaine Addiction - Drug Profile

Product Description

Mechanism Of Action

History of Events

Vaccine for Drug Abuse - Drug Profile

Product Description

Mechanism Of Action

Vaccine for Methamphetamine Addiction - Drug Profile

Product Description

Mechanism Of Action

VVZN-3 - Drug Profile

Product Description

Mechanism Of Action

XHell-053 - Drug Profile

Product Description

Mechanism Of Action

zolonicant hydrochloride - Drug Profile

Product Description

Mechanism Of Action

History of Events

Drug Addiction - Dormant Projects

Drug Addiction - Discontinued Products

Drug Addiction - Product Development Milestones

Featured News & Press Releases

Oct 04, 2021: InterveXion Therapeutics awarded federal grant to fund phase 2 study for methamphetamine use disorder

Jun 30, 2021: Embera NeuroTherapeutics announces first subject dosed in phase 2a study of EMB-001 in smoking cessation

Jun 24, 2021: Mydecine selects substance use disorder and smoking cessation for novel psychedelic molecule MYCO-004

May 07, 2021: KemPharm announces serdexmethylphenidate (SDX) has been classified as a schedule IV controlled substance by the DEA

Apr 19, 2021: InterveXion announces positive data in phase 2 study of IXT-m200 in participants with Methamphetamine use disorder

Feb 22, 2021: Entheon Biomedical announces ethics approval for in vivo DMT study

Jan 27, 2021: KemPharm receives FDA clearance to initiate KP879 clinical program for the treatment of stimulant use disorder

Dec 22, 2020: KemPharm files IND for KP879 for the treatment of Stimulant Use Disorder

Dec 09, 2020: Entheon Biomedical announces DMT drug supply agreement with Psygen Labs completion of initial DMT research drug batch and exercise of warrants

Dec 01, 2020: Entheon Biomedical announces CRO agreement with CHDR for phase 1 clinical trial; Centre for Human Drug Research led DMT study to start in 2021

Oct 05, 2020: InterveXion Therapeutics awarded federal grant to fund phase 2 study for Methamphetamine overdose

Aug 31, 2020: Embera NeuroTherapeutics announces first subject dosed in phase 2 study of EMB-001 in cocaine use disorder

Jan 30, 2020: Cerevel Therapeutics initiates phase 1 clinical trial of CVL-936, an investigational medicine in development to treat Substance Use Disorder

Dec 04, 2019: Intra-Cellular Therapies to present data on ITI-333 at the 58th annual meeting of the American College of Neuropsychopharmacology

Oct 07, 2019: BioCorRx announces capital restructuring and provides business update

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer



## List Of Tables

### LIST OF TABLES

Number of Products under Development for Drug Addiction, 2022  
Number of Products under Development by Companies, 2022  
Number of Products under Development by Companies, 2022 (Contd..1)  
Number of Products under Development by Companies, 2022 (Contd..2)  
Number of Products under Development by Universities/Institutes, 2022  
Products under Development by Companies, 2022  
Products under Development by Companies, 2022 (Contd..1)  
Products under Development by Companies, 2022 (Contd..2)  
Products under Development by Companies, 2022 (Contd..3)  
Products under Development by Universities/Institutes, 2022  
Number of Products by Stage and Target, 2022  
Number of Products by Stage and Target, 2022 (Contd..1)  
Number of Products by Stage and Mechanism of Action, 2022  
Number of Products by Stage and Mechanism of Action, 2022 (Contd..1)  
Number of Products by Stage and Route of Administration, 2022  
Number of Products by Stage and Molecule Type, 2022  
Drug Addiction - Pipeline by Adjuvance Technologies Inc, 2022  
Drug Addiction - Pipeline by Aelis Farma SAS, 2022  
Drug Addiction - Pipeline by Aether Therapeutics Inc, 2022  
Drug Addiction - Pipeline by Allaysis LLC, 2022  
Drug Addiction - Pipeline by Amygdala Neurosciences Inc, 2022  
Drug Addiction - Pipeline by Ananda Scientific Inc, 2022  
Drug Addiction - Pipeline by Aphios Corp, 2022  
Drug Addiction - Pipeline by Assertio Holdings Inc, 2022  
Drug Addiction - Pipeline by Astraea Therapeutics LLC, 2022  
Drug Addiction - Pipeline by Better Life Pharmaceuticals Inc, 2022  
Drug Addiction - Pipeline by BioCorRx Inc, 2022  
Drug Addiction - Pipeline by Camino Pharma LLC, 2022  
Drug Addiction - Pipeline by Cerevel Therapeutics Holdings Inc, 2022  
Drug Addiction - Pipeline by Charleston Laboratories Inc, 2022  
Drug Addiction - Pipeline by Chiesi Farmaceutici SpA, 2022  
Drug Addiction - Pipeline by Chiromics LLC, 2022  
Drug Addiction - Pipeline by Clear Scientific LLC, 2022  
Drug Addiction - Pipeline by Consega Pharma Inc, 2022  
Drug Addiction - Pipeline by Curemark LLC, 2022

Drug Addiction - Pipeline by D&A Pharma SAS, 2022

Drug Addiction - Pipeline by Daya Drug Discoveries Inc, 2022

Drug Addiction - Pipeline by DD Therapeutics LLC, 2022

Drug Addiction - Pipeline by Delix Therapeutics Inc, 2022

Drug Addiction - Pipeline by Denovo Biopharma LLC, 2022

Drug Addiction - Pipeline by Elysium Therapeutics Inc, 2022

Drug Addiction - Pipeline by Embera NeuroTherapeutics Inc, 2022

Drug Addiction - Pipeline by EncepHeal Therapeutics Inc, 2022

Drug Addiction - Pipeline by Ensysce Biosciences Inc, 2022

Drug Addiction - Pipeline by Entheon Biomedical Corp, 2022

Drug Addiction - Pipeline by EryDel SpA, 2022

Drug Addiction - Pipeline by F. Hoffmann-La Roche Ltd, 2022

Drug Addiction - Pipeline by Foresee Pharmaceuticals Co Ltd, 2022

Drug Addiction - Pipeline by Hua Medicine Shanghai Ltd, 2022

Drug Addiction - Pipeline by IMV Inc, 2022

Drug Addiction - Pipeline by InterveXion Therapeutics LLC, 2022

Drug Addiction - Pipeline by Intra-Cellular Therapies Inc, 2022

Drug Addiction - Pipeline by Jazz Pharmaceuticals Plc, 2022

Drug Addiction - Pipeline by Kdac Therapeutics Inc, 2022

Drug Addiction - Pipeline by KemPharm Inc, 2022

Drug Addiction - Pipeline by Kinaxis Therapeutics Pty Ltd, 2022

Drug Addiction - Pipeline by Kyorin Pharmaceutical Co Ltd, 2022

Drug Addiction - Pipeline by MAKScientific LLC, 2022

Drug Addiction - Pipeline by MEIkin Pharmaceuticals, 2022

Drug Addiction - Pipeline by Mind Medicine MindMed Inc, 2022

Drug Addiction - Pipeline by Mydecine Innovations Group Inc, 2022

Drug Addiction - Pipeline by Myosin Therapeutics Inc, 2022

Drug Addiction - Pipeline by Naprogenix Inc, 2022

Drug Addiction - Pipeline by NFL Biosciences SAS, 2022

Drug Addiction - Pipeline by Novartis AG, 2022

Drug Addiction - Pipeline by Omeros Corp, 2022

Drug Addiction - Pipeline by Ovid Therapeutics Inc, 2022

Drug Addiction - Pipeline by P2D Inc, 2022

Drug Addiction - Pipeline by PAION AG, 2022

Drug Addiction - Pipeline by Proniras Corp, 2022

Drug Addiction - Pipeline by Protagenic Therapeutics Inc, 2022

Drug Addiction - Pipeline by Qingdao Primedicine Pharmaceutical Technology Co Ltd, 2022

Drug Addiction - Pipeline by Relmada Therapeutics Inc, 2022

Drug Addiction - Pipeline by Revive Therapeutics Ltd, 2022  
Drug Addiction - Pipeline by Saniona AB, 2022  
Drug Addiction - Pipeline by Sen-Jam Pharmaceutical LLC, 2022  
Drug Addiction - Pipeline by Tonix Pharmaceuticals Holding Corp, 2022  
Drug Addiction - Pipeline by Trevena Inc, 2022  
Drug Addiction - Pipeline by Tris Pharma Inc, 2022  
Drug Addiction - Pipeline by Vallon Pharmaceuticals Inc, 2022  
Drug Addiction - Pipeline by Vivozon Inc, 2022  
Drug Addiction - Pipeline by Zelira Therapeutics Ltd, 2022  
Drug Addiction - Dormant Projects, 2022  
Drug Addiction - Dormant Projects, 2022 (Contd..1)  
Drug Addiction - Dormant Projects, 2022 (Contd..2)  
Drug Addiction - Dormant Projects, 2022 (Contd..3)  
Drug Addiction - Dormant Projects, 2022 (Contd..4)  
Drug Addiction - Discontinued Products, 2022

## List Of Figures

### LIST OF FIGURES

Number of Products under Development for Drug Addiction, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Top 10 Routes of Administration, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

## I would like to order

Product name: Drug Addiction Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/D4C681E57126EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/D4C681E57126EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

